High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.
Clinical trials
Endometrial cancer
Molecular classification
Recurrent disease
Treatment resistant disease
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
02
10
2023
accepted:
02
04
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
Although many recent advancements have been made in women's health, perhaps one of the most neglected areas of research is the diagnosis and treatment of high-grade endometrial cancer (EnCa). The molecular classification of EnCa in concert with histology was a major step forward. The integration of profiling for mismatch repair deficiency and Human Epidermal Growth Factor 2 (HER2) overexpression, can further inform treatment options, especially for drug resistant recurrent disease. Recent early phase trials suggest that regardless of subtype, combination therapy with agents that have distinct mechanisms of action is a fruitful approach to the treatment of high-grade EnCa. Unfortunately, although the importance of diagnosis and treatment of high-grade EnCa is well recognized, it is understudied compared to other gynecologic and breast cancers. There remains a tremendous need to couple molecular profiling and biomarker development with promising treatment options to inform new treatment strategies with higher efficacy and safety for all who suffer from high-grade recurrent EnCa.
Identifiants
pubmed: 38658487
doi: 10.1007/s43032-024-01544-5
pii: 10.1007/s43032-024-01544-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Nile Albright Research Foundation
ID : Nile Albright Research Foundation
Organisme : Vincent Memorial Hospital Foundation
ID : Vincent Memorial Hospital Foundation
Informations de copyright
© 2024. The Author(s), under exclusive licence to Society for Reproductive Investigation.
Références
Mahdi H, Ray-Coquard I, Lorusso D, Mirza MR, Monk BJ, Slomovitz B. Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: when is hormonal-based therapy the preferred option? Int J Gynecol Cancer 2023.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
pubmed: 36633525
doi: 10.3322/caac.21763
Shaw E, Farris M, McNeil J, Friedenreich C. Obesity and endometrial Cancer. Recent Results Cancer Res. 2016;208:107–36.
pubmed: 27909905
doi: 10.1007/978-3-319-42542-9_7
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in Endometrial Cancer Risk, Prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30.
pubmed: 27903150
pmcid: 5455320
doi: 10.1200/JCO.2016.69.4638
Zaino RJ, Kurman RJ, Diana KL, Morrow CP. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer. 1995;75(1):81–6.
pubmed: 7804981
doi: 10.1002/1097-0142(19950101)75:1<81::AID-CNCR2820750114>3.0.CO;2-F
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491–505.
pubmed: 16084259
doi: 10.1016/S0140-6736(05)67063-8
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.
pubmed: 6822361
doi: 10.1016/0090-8258(83)90111-7
Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506–19.
pubmed: 10871473
doi: 10.1067/mob.2000.107335
Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, Nejc D, Bibik R, Korczynski J, Cialkowska-Rysz A. Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci. 2010;6(6):937–44.
pubmed: 22427770
pmcid: 3302708
doi: 10.5114/aoms.2010.19305
Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021;160(1):322–32.
pubmed: 33160694
doi: 10.1016/j.ygyno.2020.10.017
Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control. 2009;16(1):46–52.
pubmed: 19078929
doi: 10.1177/107327480901600107
Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed mullerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int. 2011;2011:470795.
pubmed: 22007228
pmcid: 3189599
doi: 10.1155/2011/470795
Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13(3):295–308.
pubmed: 10757340
doi: 10.1038/modpathol.3880051
Emons G, Beckmann MW, Schmidt D, Mallmann P. Uterus commission of the Gynecological Oncology Working G: New WHO classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75(2):135–6.
pubmed: 25797956
pmcid: 4361167
doi: 10.1055/s-0034-1396256
Shields TS, Weiss NS, Voigt LF, Beresford SA. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. Epidemiology. 1999;10(6):733–8.
pubmed: 10535788
doi: 10.1097/00001648-199911000-00014
Main C, Chen X, Zhao M, Chamley LW, Chen Q. Understanding how pregnancy protects against ovarian and endometrial Cancer Development: fetal antigens may be involved. Endocrinology 2022, 163(11).
Coffin E, Dhooge M, Abou Ali E, Dermine S, Lavole J, Palmieri LJ, Chaussade S, Coriat R. [Identification and management of patients with Lynch syndrome]. Presse Med. 2019;48(9):904–14.
pubmed: 31561847
doi: 10.1016/j.lpm.2019.07.011
Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Pt 1):383–97.
pubmed: 22825101
doi: 10.1097/AOG.0b013e3182605bf1
Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2015;51(18):2747–58.
pubmed: 26597445
doi: 10.1016/j.ejca.2015.08.031
Teng F, Ma X, Yu X, Yan Y, Zhao J, Gao J, Gao C, Wang Y, Tian W, Xue F. High serum androgen and insulin concentrations increase the tendency of endometrial carcinoma. J Cancer. 2020;11(19):5656–64.
pubmed: 32913460
pmcid: 7477453
doi: 10.7150/jca.46391
Ferriss JS, Erickson BK, Shih IM, Fader AN. Uterine serous carcinoma: key advances and novel treatment approaches. Int J Gynecol Cancer. 2021;31(8):1165–74.
pubmed: 34210768
doi: 10.1136/ijgc-2021-002753
Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98(1):176–86.
pubmed: 12833470
doi: 10.1002/cncr.11484
Doll KM, Winn AN. Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis. Am J Obstet Gynecol. 2019;221(4):e318311–9.
doi: 10.1016/j.ajog.2019.05.024
Sponholtz TR, Palmer JR, Rosenberg L, Chen C, Chen Y, Clarke MA, Clendenen T, Du M, Johnson L, Liao LM, et al. Risk factors for endometrial cancer in black women. Cancer Causes Control. 2023;34(5):421–30.
pubmed: 36418803
doi: 10.1007/s10552-022-01653-z
Mukerji B, Baptiste C, Chen L, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD. Racial disparities in young women with endometrial cancer. Gynecol Oncol. 2018;148(3):527–34.
pubmed: 29307452
pmcid: 5829000
doi: 10.1016/j.ygyno.2017.12.032
Johnson AL, Medina HN, Schlumbrecht MP, Reis I, Kobetz EN, Pinheiro PS. The role of histology on endometrial cancer survival disparities in diverse Florida. PLoS ONE. 2020;15(7):e0236402.
pubmed: 32701999
pmcid: 7377497
doi: 10.1371/journal.pone.0236402
Huang AB, Huang Y, Hur C, Tergas AI, Khoury-Collado F, Melamed A, St Clair CM, Hou JY, Ananth CV, Neugut AI, et al. Impact of quality of care on racial disparities in survival for endometrial cancer. Am J Obstet Gynecol. 2020;223(3):396. e391-396 e313.
doi: 10.1016/j.ajog.2020.02.021
Yeku OO. Racial disparities and referral for genetic counseling. Cancer. 2024;130(4):505–6.
pubmed: 37889909
doi: 10.1002/cncr.35062
Clarke MA, Devesa SS, Hammer A, Wentzensen N. Racial and ethnic differences in hysterectomy-corrected uterine Corpus Cancer Mortality by Stage and histologic subtype. JAMA Oncol. 2022;8(6):895–903.
pubmed: 35511145
pmcid: 9073658
doi: 10.1001/jamaoncol.2022.0009
Rodriguez AM, Schmeler KM, Kuo YF. Disparities in endometrial cancer outcomes between non-hispanic White and hispanic women. Gynecol Oncol. 2014;135(3):525–33.
pubmed: 25449307
doi: 10.1016/j.ygyno.2014.10.021
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–23.
pubmed: 20206777
doi: 10.1016/S0140-6736(09)62163-2
Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.
pubmed: 14984936
doi: 10.1016/j.ygyno.2003.11.048
Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 (Suppl 1):S105-143.
Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on Disease-Free Survival among Women with Stage I endometrial Cancer: a Randomized Clinical Trial. JAMA. 2017;317(12):1224–33.
pubmed: 28350928
doi: 10.1001/jama.2017.2068
Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, Laframboise S, May T, Hogen LF, Covens AL, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg. 2021;156(2):157–64.
pubmed: 33175109
doi: 10.1001/jamasurg.2020.5060
Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40(1):55–65.
pubmed: 1989916
doi: 10.1016/0090-8258(91)90086-K
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–50.
pubmed: 33078978
pmcid: 7676887
doi: 10.1200/JCO.20.01076
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D’Amico R, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–85.
pubmed: 31345626
pmcid: 6722042
doi: 10.1016/S1470-2045(19)30395-X
Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O’Malley DM, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317–26.
pubmed: 31189035
pmcid: 6948006
doi: 10.1056/NEJMoa1813181
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295–309.
pubmed: 29449189
pmcid: 5840256
doi: 10.1016/S1470-2045(18)30079-2
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, et al. Ten-year comparison study of type 1 and 2 endometrial cancers: risk factors and outcomes. Gynecol Obstet Invest. 2019;84(3):290–7.
pubmed: 30602164
doi: 10.1159/000493132
Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1):26–35.
pubmed: 30741844
pmcid: 6685771
doi: 10.1097/PGP.0000000000000585
Åkesson Å, Adok C, Dahm-Kähler P. Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study. Gynecol Oncol. 2023;168:127–34.
pubmed: 36434947
doi: 10.1016/j.ygyno.2022.11.012
del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127(3):651–61.
pubmed: 23000148
doi: 10.1016/j.ygyno.2012.09.012
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van der Steen-Banasik E, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89(2):201–9.
pubmed: 12713981
doi: 10.1016/S0090-8258(03)00126-4
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer. 2009;19(3):314–20.
pubmed: 19407552
doi: 10.1111/IGC.0b013e3181a7f71e
Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol Oncol. 2006;103(1):281–7.
Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118(1):14–8.
pubmed: 20434198
doi: 10.1016/j.ygyno.2010.04.005
Ren Y, Shan B, Shi D, Wang H. Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study. BMC Cancer. 2014;14:135.
pubmed: 24571733
pmcid: 3941750
doi: 10.1186/1471-2407-14-135
Liu J, Emond B, Maiese EM, Lafeuille MH, Lefebvre P, Ghelerter I, Wu C, Hurteau JA, Thaker PH. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States. Curr Med Res Opin. 2022;38(11):1935–45.
pubmed: 35975577
doi: 10.1080/03007995.2022.2112872
Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Gynecologic Oncology Group s: phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10–4.
pubmed: 14751131
doi: 10.1016/j.ygyno.2003.11.008
Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010(12):Cd007926.
McConechy MK, Talhouk A, Leung S, Chiu D, Yang W, Senz J, Reha-Krantz LJ, Lee CH, Huntsman DG, Gilks CB, et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin Cancer Res. 2016;22(12):2865–73.
pubmed: 26763250
doi: 10.1158/1078-0432.CCR-15-2233
Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
doi: 10.1038/nature12113
Horeweg N, Nout RA, Jurgenliemk-Schulz IM, Lutgens L, Jobsen JJ, Haverkort MAD, Mens JWM, Slot A, Wortman BG, de Boer SM, et al. Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial Cancer. J Clin Oncol. 2023;41(27):4369–80.
pubmed: 37487144
pmcid: 10522107
doi: 10.1200/JCO.23.00062
Conde-Perezprina JC, Leon-Galvan MA, Konigsberg M. DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging. Oxid Med Cell Longev. 2012;2012:728430.
pubmed: 23213348
pmcid: 3504481
doi: 10.1155/2012/728430
Germano G, Amirouchene-Angelozzi N, Rospo G, Bardelli A. The clinical impact of the genomic Landscape of Mismatch Repair-deficient cancers. Cancer Discov. 2018;8(12):1518–28.
pubmed: 30442708
doi: 10.1158/2159-8290.CD-18-0150
Wang QX, Qu CH, Gao YH, Ding PR, Yun JP, Xie D, Cai MY. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers. Exp Hematol Oncol. 2021;10(1):2.
pubmed: 33397433
pmcid: 7784284
doi: 10.1186/s40164-020-00193-z
Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20:16.
pubmed: 31956294
pmcid: 6958913
doi: 10.1186/s12935-019-1091-8
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–57.
pubmed: 9823339
Kullmann F, Strissel PL, Strick R, Stoehr R, Eckstein M, Bertz S, Wullich B, Sikic D, Wach S, Taubert H, et al. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. J Clin Pathol. 2023;76(2):126–32.
pubmed: 34583948
doi: 10.1136/jclinpath-2021-207855
Lee CT, Chow NH, Chen YL, Ho CL, Yeh YM, Lin SC, Lin PC, Lin BW, Chu CA, Tsai HW, et al. Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer. Pathol Res Pract. 2021;217:153288.
pubmed: 33276219
doi: 10.1016/j.prp.2020.153288
Richman S. Deficient mismatch repair: read all about it (review). Int J Oncol. 2015;47(4):1189–202.
pubmed: 26315971
pmcid: 4583524
doi: 10.3892/ijo.2015.3119
Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, et al. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Int J Gynecol Cancer. 2023;33(4):504–13.
pubmed: 36750267
pmcid: 10086481
doi: 10.1136/ijgc-2022-004026
Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, Sawchyn B, Gjoerup O, Meng W, Skoletsky J, et al. Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17(3):e0264138.
pubmed: 35294956
pmcid: 8926248
doi: 10.1371/journal.pone.0264138
Washington CR, Moore KN. PARP inhibitors in the treatment of ovarian cancer: a review. Curr Opin Obstet Gynecol. 2021;33(1):1–6.
pubmed: 33369580
doi: 10.1097/GCO.0000000000000675
Dong L, Wang T, Li N, Yao H, Ying J, Wu L, Yuan G. Prevalence and prognostic relevance of homologous recombination repair gene mutations in Uterine Serous Carcinoma. Cells 2022, 11(22).
Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, et al. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecol Oncol. 2022;166(2):351–7.
pubmed: 35641325
doi: 10.1016/j.ygyno.2022.05.021
Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer. 2008;18(1):14–21.
pubmed: 17451461
doi: 10.1111/j.1525-1438.2007.00946.x
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126–32.
pubmed: 15284264
doi: 10.1200/JCO.2004.11.154
Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci. 2012;103(5):926–32.
pubmed: 22329832
pmcid: 7659356
doi: 10.1111/j.1349-7006.2012.02240.x
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O’Brien T, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8(5):1271–9.
pubmed: 12006548
Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014;138(3):343–50.
pubmed: 24576030
doi: 10.5858/arpa.2012-0416-RA
Buza N. HER2 testing in Endometrial Serous Carcinoma: time for standardized Pathology Practice to meet the clinical demand. Arch Pathol Lab Med. 2021;145(6):687–91.
pubmed: 32649220
doi: 10.5858/arpa.2020-0207-RA
Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):3–9.
pubmed: 17945336
doi: 10.1016/j.ygyno.2007.09.007
Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18(2):138–43.
pubmed: 10202671
doi: 10.1097/00004347-199904000-00007
Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24(15):2376–85.
pubmed: 16710036
doi: 10.1200/JCO.2005.03.4827
Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391–7.
pubmed: 16116605
doi: 10.1002/cncr.21308
Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15–20.
pubmed: 19840887
doi: 10.1016/j.ygyno.2009.09.025
Hashem S, Zare SY, Fadare O. HER2 Status Assessment in Endometrial Serous Carcinoma: comparative analysis of two proposed testing and interpretation algorithms. Int J Gynecol Pathol 2023.
Buza N, Euscher ED, Matias-Guiu X, McHenry A, Oliva E, Ordulu Z, Parra-Herran C, Rottmann D, Turner BM, Wong S, et al. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. Mod Pathol. 2021;34(6):1194–202.
pubmed: 33536574
doi: 10.1038/s41379-021-00746-5
Diver EJ, Foster R, Rueda BR, Growdon WB. The therapeutic challenge of Targeting HER2 in Endometrial Cancer. Oncologist. 2015;20(9):1058–68.
pubmed: 26099744
doi: 10.1634/theoncologist.2015-0149
Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, et al. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts. Clin Cancer Res. 2014;20(24):6517–28.
pubmed: 25294905
pmcid: 4268047
doi: 10.1158/1078-0432.CCR-14-1647
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O’Malley DM, et al. Randomized phase II Trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018;36(20):2044–51.
pubmed: 29584549
doi: 10.1200/JCO.2017.76.5966
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O’Malley DM, et al. Randomized phase II Trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928–35.
pubmed: 32601075
pmcid: 8792803
doi: 10.1158/1078-0432.CCR-20-0953
Lin CY, Chao A, Wang TH, Hsueh S, Lee YS, Wu TI, Chao AS, Huang HJ, Chou HH, Chang TC, et al. A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. J Mol Med (Berl). 2014;92(9):969–81.
pubmed: 24820961
doi: 10.1007/s00109-014-1163-0
Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 2014;135(1):142–8.
pubmed: 25124161
doi: 10.1016/j.ygyno.2014.08.006
Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, et al. Dual HER2/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 2015;14(11):2519–26.
pubmed: 26333383
pmcid: 4636465
doi: 10.1158/1535-7163.MCT-15-0383
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9.
pubmed: 24132290
pmcid: 3927368
doi: 10.1038/nature12634
Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010;117(3):473–6.
pubmed: 20347480
doi: 10.1016/j.ygyno.2010.02.022
Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials Group. J Clin Oncol. 2011;29(24):3278–85.
pubmed: 21788564
pmcid: 3158598
doi: 10.1200/JCO.2010.34.1578
Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012;18(20):5796–805.
pubmed: 22927482
doi: 10.1158/1078-0432.CCR-12-1158
Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JJ 2nd, Zweizig SL, Van Le L, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132(3):585–92.
Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, van der Graaf WT, Oyen WJ, Ottevanger PB, van Herpen CM. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase ib results and prediction of clinical outcome with FDG-PET/CT. Target Oncol. 2014;9(4):339–47.
pubmed: 24577626
doi: 10.1007/s11523-014-0309-x
Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, et al. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol. 2016;140(3):450–6.
pubmed: 26731724
doi: 10.1016/j.ygyno.2015.12.025
Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway R, Braly P, Matei D, Morosky A, Dodion PF, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108(5):1021–6.
pubmed: 23403817
pmcid: 3619076
doi: 10.1038/bjc.2013.59
Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135(2):184–9.
pubmed: 25173583
doi: 10.1016/j.ygyno.2014.06.033
Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33(31):3576–82.
pubmed: 26077241
doi: 10.1200/JCO.2014.58.8871
Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–9.
pubmed: 20681032
doi: 10.1002/cncr.25515
Ray-Coquard I, Favier L, Weber B, Roemer-Becuwe C, Bougnoux P, Fabbro M, Floquet A, Joly F, Plantade A, Paraiso D, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013;108(9):1771–7.
pubmed: 23612453
pmcid: 3658508
doi: 10.1038/bjc.2013.183
Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–6.
pubmed: 25624430
pmcid: 4348638
doi: 10.1200/JCO.2014.58.3401
Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study. Gynecol Oncol. 2022;164(3):481–91.
pubmed: 35063278
doi: 10.1016/j.ygyno.2021.12.031
Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, et al. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014;5(10):3029–38.
pubmed: 24912489
pmcid: 4102789
doi: 10.18632/oncotarget.1799
Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, et al. A phase ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730–8.
pubmed: 25500057
doi: 10.1158/1078-0432.CCR-14-1814
Starks DC, Rojas-Espaillat L, Meissner T, Williams CB. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors. Gynecol Oncol. 2022;166(3):403–9.
pubmed: 35843739
doi: 10.1016/j.ygyno.2022.07.005
Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, et al. Safety and Efficacy of the mTOR inhibitor, Vistusertib, Combined with Anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial Cancer: the VICTORIA Multicenter, Open-label, phase 1/2 Randomized Clinical Trial. JAMA Oncol. 2022;8(7):1001–9.
pubmed: 35551299
pmcid: 9100474
doi: 10.1001/jamaoncol.2022.1047
Lee JB, Jung M, Beom SH, Kim GM, Kim HR, Choi HJ, Sohn JH, Ahn JB, Rha SY, Chung HC. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Invest New Drugs. 2021;39(5):1366–74.
pubmed: 33723724
pmcid: 8426297
doi: 10.1007/s10637-021-01085-7
Colombo I, Genta S, Martorana F, Guidi M, Frattini M, Samartzis EP, Brandt S, Gaggetta S, Moser L, Pascale M, et al. Phase I dose-escalation study of the dual PI3K-mTORC1/2 inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in patients with Advanced Solid tumors. Clin Cancer Res. 2021;27(18):5012–9.
pubmed: 34266890
doi: 10.1158/1078-0432.CCR-21-1402
Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, et al. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: an NRG Oncology/GOG study. Gynecol Oncol. 2019;155(3):420–8.
pubmed: 31623857
pmcid: 6922584
doi: 10.1016/j.ygyno.2019.09.024
Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, et al. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020;147(2):413–22.
pubmed: 31714586
doi: 10.1002/ijc.32783
Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, et al. A first-in-human phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with Advanced Cancer. Clin Cancer Res. 2018;24(14):3253–62.
pubmed: 29636360
doi: 10.1158/1078-0432.CCR-17-3421
Wheler J, Mutch D, Lager J, Castell C, Liu L, Jiang J, Traynor AM. Phase I dose-escalation study of pilaralisib (SAR245408, XL147) in combination with paclitaxel and carboplatin in patients with solid tumors. Oncologist. 2017;22(4):377–e337.
pubmed: 28275119
pmcid: 5388374
doi: 10.1634/theoncologist.2016-0257
Wainberg ZA, Alsina M, Soares HP, Brana I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, et al. A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer. Target Oncol. 2017;12(6):775–85.
pubmed: 29067643
pmcid: 5700209
doi: 10.1007/s11523-017-0530-5
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br J Cancer. 2017;116(3):303–9.
pubmed: 28072765
pmcid: 5294485
doi: 10.1038/bjc.2016.430
Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, et al. First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res. 2016;22(8):1932–9.
pubmed: 26603258
doi: 10.1158/1078-0432.CCR-15-1665
Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonzalez-Martin A, et al. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016;142(1):62–9.
pubmed: 27103175
doi: 10.1016/j.ygyno.2016.04.019
Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–53.
pubmed: 25528496
doi: 10.1016/j.ygyno.2014.12.019
Bendell JC, Kurkjian C, Infante JR, Bauer TM, Burris HA 3rd, Greco FA, Shih KC, Thompson DS, Lane CM, Finney LH, et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs. 2015;33(2):463–71.
Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(1):95–102.
pubmed: 22638798
pmcid: 4086794
doi: 10.1007/s00280-012-1889-8
Liu J, Oza AM, Colombo N, Oaknin A. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2022;32(1):89–92.
pubmed: 34716177
doi: 10.1136/ijgc-2021-003144
Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, Khalique S, Tai J, Attygalle A, Vroobel K, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021;31(11):1471–5.
pubmed: 34518240
pmcid: 8573414
doi: 10.1136/ijgc-2021-002973
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, et al. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. Int J Gynecol Cancer. 2023;33(8):1208–14.
pubmed: 37380217
pmcid: 10711936
doi: 10.1136/ijgc-2023-004491
Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M et al. Combination of EphA2- and Wee1-targeted therapies in Endometrial Cancer. Int J Mol Sci 2023, 24(4).
Takebe N, Naqash AR, O’Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz R, et al. Safety, antitumor activity, and biomarker analysis in a phase I trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Clin Cancer Res. 2021;27(14):3834–44.
pubmed: 33863809
pmcid: 8282703
doi: 10.1158/1078-0432.CCR-21-0329
Meng X, Bi J, Li Y, Yang S, Zhang Y, Li M, Liu H, Li Y, McDonald ME, Thiel KW et al. AZD1775 increases sensitivity to olaparib and gemcitabine in cancer cells with p53 mutations. Cancers (Basel) 2018, 10(5).
Takeuchi M, Tanikawa M, Nagasaka K, Oda K, Kawata Y, Oki S, Agapiti C, Sone K, Miyagawa Y, Hiraike H et al. Anti-tumor Effect of Inhibition of DNA damage response proteins, ATM and ATR, in endometrial cancer cells. Cancers (Basel) 2019, 11(12).
Teng PN, Bateman NW, Darcy KM, Hamilton CA, Maxwell GL, Bakkenist CJ, Conrads TP. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol. 2015;136(3):554–61.
pubmed: 25560806
pmcid: 4382918
doi: 10.1016/j.ygyno.2014.12.035
O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr., Safra T, Italiano A, Mileshkin L, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61.
pubmed: 34990208
pmcid: 8887941
doi: 10.1200/JCO.21.01874
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48.
pubmed: 35045221
doi: 10.1056/NEJMoa2108330
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159–70.
pubmed: 36972022
pmcid: 10351614
doi: 10.1056/NEJMoa2302312
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–58.
pubmed: 36972026
doi: 10.1056/NEJMoa2216334
Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–94.
pubmed: 31461377
pmcid: 9798913
doi: 10.1200/JCO.19.01021
Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, et al. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer. JAMA Oncol. 2022;8(9):1317–22.
pubmed: 35900726
pmcid: 9335244
doi: 10.1001/jamaoncol.2022.2181
Hollebecque A, Chung HC, de Miguel MJ, Italiano A, Machiels JP, Lin CC, Dhani NC, Peeters M, Moreno V, Su WC, et al. Safety and antitumor activity of alpha-PD-L1 antibody as monotherapy or in combination with alpha-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors. Clin Cancer Res. 2021;27(23):6393–404.
pubmed: 34465599
doi: 10.1158/1078-0432.CCR-21-0261
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses. J Immunother Cancer. 2019;7(1):197.
pubmed: 31345267
pmcid: 6657373
doi: 10.1186/s40425-019-0680-3
Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O’Cearbhaill R, et al. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: a randomized open-label phase 2 study. Gynecol Oncol. 2023;169:64–9.
pubmed: 36512912
doi: 10.1016/j.ygyno.2022.11.028
Post CCB, Westermann AM, Boere IA, Witteveen PO, Ottevanger PB, Sonke GS, Lalisang RI, Putter H, Meershoek-Klein Kranenbarg E, Braak J, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol. 2022;165(2):223–9.
pubmed: 35287967
doi: 10.1016/j.ygyno.2022.02.025
Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C et al. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer 2022, 10(3).
Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17(4–6):89–95.
pubmed: 25457975
doi: 10.1016/j.drup.2014.10.002
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA Study. J Clin Oncol. 2023;41(13):2436–45.
pubmed: 36716407
pmcid: 10150846
doi: 10.1200/JCO.22.01900
Li X, Zhou S, Abrahams CL, Krimm S, Smith J, Bajjuri K, Stephenson HT, Henningsen R, Hanson J, Heibeck TH, et al. Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers. Mol Cancer Ther. 2023;22(2):155–67.
pubmed: 36459691
doi: 10.1158/1535-7163.MCT-22-0322
Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, et al. In vitro and in vivo activity of IMGN853, an antibody-drug Conjugate Targeting Folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018;17(5):1003–11.
pubmed: 29440294
pmcid: 5932245
doi: 10.1158/1535-7163.MCT-17-0930
Moore KN, Borghaei H, O’Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080–7.
pubmed: 28440955
doi: 10.1002/cncr.30736
Aikawa T, Ogino J, Aikawa N, Oyama-Manabe N. Pericarditis with increased vascular permeability after COVID-19 vaccination. Intern Med. 2022;61(10):1623–4.
pubmed: 35314555
pmcid: 9177361
doi: 10.2169/internalmedicine.9407-22
Guerrini G, Magri D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol. 2022;17(6):570–6.
pubmed: 35710950
doi: 10.1038/s41565-022-01129-w
Rauf A, Abu-Izneid T, Khalil AA, Hafeez N, Olatunde A, Rahman M, Semwal P, Al-Awthan YS, Bahattab OS, Khan IN, et al. Nanoparticles in clinical trials of COVID-19: an update. Int J Surg. 2022;104:106818.
pubmed: 35953020
pmcid: 9359769
doi: 10.1016/j.ijsu.2022.106818
Tsilingiris D, Vallianou NG, Karampela I, Liu J, Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabol Open. 2022;13:100159.
pubmed: 34938983
doi: 10.1016/j.metop.2021.100159
Mosselhy DA, Virtanen J, Kant R, He W, Elbahri M, Sironen T. COVID-19 pandemic: what about the safety of anti-coronavirus nanoparticles? Nanomaterials (Basel) 2021, 11(3).
Ebeid K, Meng X, Thiel KW, Do AV, Geary SM, Morris AS, Pham EL, Wongrakpanich A, Chhonker YS, Murry DJ, et al. Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol. 2018;13(1):72–81.
pubmed: 29203914
doi: 10.1038/s41565-017-0009-7
Gong X, Pu X, Wang J, Yang L, Cui Y, Li L, Sun X, Liu J, Bai J, Wang Y. Enhancing of nanocatalyst-driven chemodynaminc therapy for endometrial cancer cells through inhibition of PINK1/Parkin-mediated mitophagy. Int J Nanomed. 2021;16:6661–79.
doi: 10.2147/IJN.S329341